← brief for 2026-08-26 · Slowing decline

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Key takeaways

A large Phase III trial will test if adding Baxdrostat to the diabetes drug dapagliflozin helps protect kidneys and lowers heart death risk in people with chronic kidney disease and high blood pressure. There are no results yet—the study is ongoing.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-26
https://clinicaltrials.gov/study/NCT06742723